shutterstock_1364456177_madamf
madamF / Shutterstock.com
19 August 2021GenericsAlex Baldwin

Fed Circ upholds three Teva patents, axes others

The  US Court of Appeals for the Federal Circuit has affirmed US  Patent Trial and Appeal Board’s (PTAB) decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
2 April 2024   Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.
Generics
28 March 2024   Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.
Generics
18 February 2024   While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.